PPARγ is a therapeutic target that has been exploited fortreatment of type II diabetes mellitus (T2DM) with agonist drugs.Since PPARγ is expressed by many hematopoietic, mesodermal andepithelial cancers, agonist drugs were tested and shown to haveboth preclinical and clinical anticancer activities. The gene discussed is PPARG; the disease is cancer.